axitinib,nivolumab,ipilimumab,Pembrolizumab,Lenalidomide,Sunitinib
pfizer,bms,merck
['nivo', 'axi/', 'ipi/']
4 and 5 year updated os hrs for len/pembo and axi/pembo = 0.79 &amp; 0.84 respectively. initial data cuts had lower hrs ~0.6. the drift is partly driven by the good risk group (hrs=1) &amp; subsequent therapy. hrs in int/poor risk 0.74 + 0.76 (ipi/nivo= ~0.7 at similar data cuts) #asco23 
Interested in Urology Cancers, biomarkers and drug development.